T2 Biosystems launches sepsis trial

September 11, 2013 by Brad Perriello

T2 Biosystems launches a clinical trial of its T2Candida test to detect Candida, a leading cause of hospital-acquired infections that can lead to deadly cases of sepsis.

T2 Biosystems launches sepsis trial

T2 Biosystems said it's launched a clinical trial of its MR-based test for a fungus that's a common cause of deadly hospital-acquired infections.

The Lexington, Mass.-based company said it plans to use the study results to back a regulatory submission for the T2Candida test for the Candida fungus, estimated to cause some 100,000 cases of candidemia each year in the U.S.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.


Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp